Drug intelligence / Profile preview

DHP-500

Development stage: Unknown
Administration: Oral, Subcutaneous, Intraperitoneal

Overview

DHP-500 is referenced as an intervention in a Phase II randomized, double-blind clinical trial evaluating its efficacy and safety for the treatment of dry eye syndrome. The publicly available registry information does not provide detailed pharmacological characteristics, chemical composition, or mechanism of action. No additional authoritative references or regulatory documentation were identified matching DHP-500 to a marketed pharmaceutical, dietary supplement, or previously characterized compound[8].

Brand names: DHP-500DHP500DHP 500
Other names: DHP-500DHP500DHP 500

Targets

LTCC (Voltage-gated calcium channel (L-type))

Beyond the preview

Go deeper on DHP-500.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DHP-500.

Explore the full profile